Author information
1 Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA.
Abstract
Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.